首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Injectable Systems for Intra-Articular Delivery of Mesenchymal Stromal Cells for Cartilage Treatment: A Systematic Review of Preclinical and Clinical Evidence
【2h】

Injectable Systems for Intra-Articular Delivery of Mesenchymal Stromal Cells for Cartilage Treatment: A Systematic Review of Preclinical and Clinical Evidence

机译:关节内间充质基质细胞软骨内治疗的可注射系统:临床前和临床证据的系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Stem cell-based therapy is a promising approach to treat cartilage lesions and clinical benefits have been reported in a number of studies. However, the efficacy of cell injection procedures may be impaired by cell manipulation and damage as well as by cell dissemination to non-target tissues. To overcome such issues, mesenchymal stromal cell (MSC) delivery may be performed using injectable vehicles as containment systems that further provide a favorable cell microenvironment. The aim of this systematic review was to analyze the preclinical and clinical literature on platelet-rich plasma (PRP), hyaluronic acid (HA), and hydrogels for the delivery of MSCs. The systematic literature search was performed using the PubMed and Web of science databases with the following string: “(stem cells injection) AND (platelet rich plasma OR PRP OR platelet concentrate OR biomaterials OR hyaluronic acid OR hydrogels)”: 40 studies (19 preclinical and 21 clinical) met the inclusion criteria. This review revealed an increasing interest on the use of injectable agents for MSC delivery. However, while negligible adverse events and promising clinical outcomes were generally reported, the prevalence of low quality studies hinders the possibility to demonstrate the real benefits of using such injectable systems. Specific studies must be designed to clearly demonstrate the added benefits of these systems to deliver MSCs for the treatment of cartilage lesions and osteoarthritis.
机译:基于干细胞的疗法是治疗软骨损伤的一种有前途的方法,并且在许多研究中均已报道了临床益处。但是,细胞注射程序的功效可能会因细胞操纵和损伤以及细胞向非靶组织的扩散而受到损害。为了克服这些问题,可以使用可注射媒介物作为包含系统的间充质基质细胞(MSC)传递,进一步提供有利的细胞微环境。该系统评价的目的是分析富含血小板的血浆(PRP),透明质酸(HA)和水凝胶用于MSC递送的临床前和临床文献。使用PubMed和Web of Science数据库通过以下字符串进行系统的文献检索:“(干细胞注射)AND(富含血小板的血浆或PRP或血小板浓缩物或生物材料或透明质酸或水凝胶)”:40项研究(临床前19项)和21个临床实验室)符合纳入标准。这项审查表明对使用可注射药物进行MSC递送越来越感兴趣。然而,尽管一般报道的不良事件和可预见的临床结果可忽略不计,但低质量研究的普遍性阻碍了证明使用这种注射系统的真正益处的可能性。必须设计特定的研究来清楚地证明这些系统为运送MSCs治疗软骨病变和骨关节炎所带来的额外好处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号